159 related articles for article (PubMed ID: 36502925)
21. Molecular analysis of colorectal cancer tumors from patients with mismatch repair proficient hereditary nonpolyposis colorectal cancer suggests novel carcinogenic pathways.
Sánchez-de-Abajo A; de la Hoya M; van Puijenbroek M; Tosar A; López-Asenjo JA; Díaz-Rubio E; Morreau H; Caldes T
Clin Cancer Res; 2007 Oct; 13(19):5729-35. PubMed ID: 17908962
[TBL] [Abstract][Full Text] [Related]
22. β-catenin and K-ras mutations and RASSF1A promoter methylation in Taiwanese colorectal cancer patients.
Chen SP; Wu CC; Huang SY; Kang JC; Chiu SC; Yang KL; Pang CY
Genet Test Mol Biomarkers; 2012 Nov; 16(11):1277-81. PubMed ID: 23009572
[TBL] [Abstract][Full Text] [Related]
23. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability.
Pfister SX; Ahrabi S; Zalmas LP; Sarkar S; Aymard F; Bachrati CZ; Helleday T; Legube G; La Thangue NB; Porter AC; Humphrey TC
Cell Rep; 2014 Jun; 7(6):2006-18. PubMed ID: 24931610
[TBL] [Abstract][Full Text] [Related]
24. Effect of β-catenin alterations in the prognosis of patients with sporadic colorectal cancer.
Rafael S; Veganzones S; Vidaurreta M; de la Orden V; Maestro ML
J Cancer Res Ther; 2014; 10(3):591-6. PubMed ID: 25313745
[TBL] [Abstract][Full Text] [Related]
25. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-21 promotes tumour malignancy via increased nuclear translocation of β-catenin and predicts poor outcome in APC-mutated but not in APC-wild-type colorectal cancer.
Lin PL; Wu DW; Huang CC; He TY; Chou MC; Sheu GT; Lee H
Carcinogenesis; 2014 Oct; 35(10):2175-82. PubMed ID: 24832083
[TBL] [Abstract][Full Text] [Related]
27. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study.
Kirzin S; Marisa L; Guimbaud R; De Reynies A; Legrain M; Laurent-Puig P; Cordelier P; Pradère B; Bonnet D; Meggetto F; Portier G; Brousset P; Selves J
PLoS One; 2014; 9(8):e103159. PubMed ID: 25083765
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms in governing genomic stability and tumor suppression by the SETD2 H3K36 methyltransferase.
Lam UTF; Chen ES
Int J Biochem Cell Biol; 2022 Mar; 144():106155. PubMed ID: 34990836
[TBL] [Abstract][Full Text] [Related]
29. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
[TBL] [Abstract][Full Text] [Related]
30. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
31. JMJD2C promotes colorectal cancer metastasis via regulating histone methylation of MALAT1 promoter and enhancing β-catenin signaling pathway.
Wu X; Li R; Song Q; Zhang C; Jia R; Han Z; Zhou L; Sui H; Liu X; Zhu H; Yang L; Wang Y; Ji Q; Li Q
J Exp Clin Cancer Res; 2019 Oct; 38(1):435. PubMed ID: 31665047
[TBL] [Abstract][Full Text] [Related]
32. Mutations in SETD2 cause a novel overgrowth condition.
Luscan A; Laurendeau I; Malan V; Francannet C; Odent S; Giuliano F; Lacombe D; Touraine R; Vidaud M; Pasmant E; Cormier-Daire V
J Med Genet; 2014 Aug; 51(8):512-7. PubMed ID: 24852293
[TBL] [Abstract][Full Text] [Related]
33. SETD2 as a regulator of N6-methyladenosine RNA methylation and modifiers in cancer.
Kumari S; Muthusamy S
Eur J Cancer Prev; 2020 Nov; 29(6):556-564. PubMed ID: 33021769
[TBL] [Abstract][Full Text] [Related]
34. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations.
Roberti A; Dobay MP; Bisig B; Vallois D; Boéchat C; Lanitis E; Bouchindhomme B; Parrens MC; Bossard C; Quintanilla-Martinez L; Missiaglia E; Gaulard P; de Leval L
Nat Commun; 2016 Sep; 7():12602. PubMed ID: 27600764
[TBL] [Abstract][Full Text] [Related]
35. β-Catenin accumulation and S33F mutation of CTNNB1 gene in colorectal cancer in Saudi Arabia.
Alomar SY; Mansour L; Abuderman A; Alkhuriji A; Arafah M; Alwasel S; Harrath AH; Almutairi M; Trayhyrn P; Dar JA
Pol J Pathol; 2016 Jun; 67(2):156-62. PubMed ID: 27543871
[TBL] [Abstract][Full Text] [Related]
36. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
37. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers.
Chen R; Zhao WQ; Fang C; Yang X; Ji M
J Cancer; 2020; 11(11):3349-3356. PubMed ID: 32231741
[TBL] [Abstract][Full Text] [Related]
38. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Yuan H; Li N; Fu D; Ren J; Hui J; Peng J; Liu Y; Qiu T; Jiang M; Pan Q; Han Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Sep; 127(9):3375-3391. PubMed ID: 28825595
[TBL] [Abstract][Full Text] [Related]
39. Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.
Jiang C; He C; Wu Z; Li F; Xiao J
Biochem Biophys Res Commun; 2018 Jul; 502(3):382-388. PubMed ID: 29842882
[TBL] [Abstract][Full Text] [Related]
40. SETD2 histone modifier loss in aggressive GI stromal tumours.
Huang KK; McPherson JR; Tay ST; Das K; Tan IB; Ng CC; Chia NY; Zhang SL; Myint SS; Hu L; Rajasegaran V; Huang D; Loh JL; Gan A; Sairi AN; Sam XX; Dominguez LT; Lee M; Soo KC; Ooi LL; Ong HS; Chung A; Chow PK; Wong WK; Selvarajan S; Ong CK; Lim KH; Nandi T; Rozen S; Teh BT; Quek R; Tan P
Gut; 2016 Dec; 65(12):1960-1972. PubMed ID: 26338826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
